R&D channel feed

No­var­tis joins forces with LA tech com­pa­ny Sci­ence 37 to launch vir­tu­al clin­i­cal tri­als

8 years ago

Flanked by ri­vals and skep­tics, Es­pe­ri­on flips pos­i­tive da­ta on first PhI­II for a po­ten­tial­ly game-chang­ing cho­les­terol pill

8 years ago
Pharma

As killer virus out­breaks hit un­prece­dent­ed lev­els, non­prof­it hands $37.5M to Themis to tack­le Las­sa/MERS vac­cines

8 years ago

Cam­bridge star Ma­gen­ta teams up with Hei­del­berg on bone mar­row R&D pact that in­cludes $334M in po­ten­tial mile­stones

8 years ago
Pharma

Stock flies high on Clear­side’s PhI­II mac­u­lar ede­ma tri­al re­sults as drug im­proves vi­sion

8 years ago
Pharma

Watch out be­low: Der­mi­ra ax­es ac­ne drug af­ter a cat­a­stroph­ic PhI­II fail­ure

8 years ago

San­thera’s Rax­one fails NIH’s MS study in lat­est set­back, shares plunge

8 years ago

Cel­gene hands over $101M in cash to launch a re­search col­lab­o­ra­tion with pro­tein play­er Vi­vid­ion

8 years ago
Pharma

Bio­gen, Ab­b­Vie yank MS drug Zin­bry­ta off the mar­ket in the wake of en­cephali­tis cas­es

8 years ago

Roche, Io­n­is her­ald a big win in ear­ly-stage Hunt­ing­ton’s dis­ease tri­al, demon­strate dis­ease mod­i­fy­ing po­ten­tial

8 years ago

No­var­tis wants to be a leader in a new gen­er­a­tion of pre­scrip­tion dig­i­tal med pro­grams, pairs with Pear

8 years ago
Pharma

Di­al­ing down the tox­ic ef­fects of ra­di­a­tion on can­cer pa­tients, Galera gets break­through sta­tus on Phase IIb da­ta

8 years ago

Cel­gene shak­en again af­ter the FDA kicks back their mar­ket­ing ap­pli­ca­tion on block­buster hope­ful ozan­i­mod

8 years ago

J&J col­lab­o­rates with Aldeyra on new drugs for sys­temic in­flam­ma­to­ry dis­eases

8 years ago
Pharma

Stock nose­dives for car­dio­vas­cu­lar drug­mak­er Ar­ca fol­low­ing Phase IIb AF fail­ure

8 years ago

Ob­sE­va high­lights a pos­i­tive da­ta point from its PhI­II study of new fer­til­i­ty drug, beats a path to reg­u­la­tors

8 years ago

Mer­ck­'s melanoma drug shows ear­ly promise for re­sis­tant can­cers in PhI tri­al

8 years ago

The Trump ef­fect: PwC re­port says the FDA has slammed the brakes on sig­nif­i­cant new drug reg­u­la­tions

8 years ago
Pharma

Stem cell co Mesoblast re­ports PhI­II tri­al suc­cess in chil­dren with GVHD

8 years ago

Bris­tol-My­ers ax­es 107 more staffers as it com­pletes an R&D over­haul

8 years ago
Pharma

All in: Gilead maps a $3.15B gene edit­ing al­liance with Sang­amo for off-the-shelf CAR-T drugs

8 years ago

Aban­doned by J&J, fad­ed hep C star Achillion ax­es staff and maps path to PhII read­outs

8 years ago
Pharma

In a turf war with Eli Lil­ly, No­vo Nordisk steps off with pos­i­tive PhI­II for its chal­leng­ing oral GLP-1 drug

8 years ago

GW Phar­ma shares dent­ed af­ter cannabi­noid drug fails a PhI­Ia study on fo­cal seizures

8 years ago
First page Previous page 278279280281282283284 Next page Last page
A service from the Financial Times